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Several studies have shown a strong independent association between chronic
kidney disease (CKD) and cardiovascular events, including death, heart failure, and
myocardial infarction. Recent clinical trials extend this range of adverse cardiovas-
cular events, also including ventricular arrhythmias and sudden cardiac death.
Furthermore, other studies suggest structural remodeling of the heart and electro-
physiological alterations in this population. These processes may explain the
increased risk of arrhythmia in kidney disease and help to identify patients who are
at increased risk of sudden cardiac death. Sympathetic hyperactivity is well known
to increase cardiovascular risk in CKD patients and is a hallmark of essential hy-
pertensive state that occurs early in the clinical course of the disease. In CKD, the
sympathetic hyperactivity seems to be expressed at the earliest clinical stage of the
disease, showing a direct relationship with the severity of the condition of renal
failure, being more pronounced in the terminal stage of CKD. The sympathetic
efferent and afferent neural activity in kidney failure is a key mediator for the
maintenance and progression of the disease. The aim of this review was to show
that the feedback loop of this cycle, due to adrenergic hyperactivity, also aggravates
many of the risk factors responsible for causing sudden cardiac death and may be a
potential target modiﬁable by percutaneous renal sympathetic denervation. If it is
feasible and effective in end-stage renal disease, little is known.
Copyright © 2016. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chronic kidney disease (CKD) is a major public health
problem worldwide. The main consequences of CKD include
loss of renal function leading to end-stage renal disease (ESRD),
accelerated cardiovascular disease (CVD) and death. In 2011, the
number of patients receiving treatment for ESRD in the United, Faculdade de Medicina
Pires de Campos, 05403
n).
ty of Nephrology. Published b
/4.0/).States of America (USA) reached a new milestone, 615,899
cases. The prevalence of dialysis population (including perito-
neal dialysis and other modalities) reached 430,273 at
December 31, and the prevalence of the number of kidney
transplants reached 185,626 [1].
Analyses of developed countries have shown that 2e3% of
health expenditures are used to provide treatment for patients
with ESRD, although they represented only 0.02e0.03% of total
population [2]. ESRD expenses were estimated at 6.4% of the
entire budget of the US health care system in 2006, 4.1% of the
total health budget in Japan, and 3.24% of the expenditure of
the national health system in other countries as South Korea. As
the costs of the national American health care system for they Elsevier. This is an open access article under the CC BY-NC-ND license
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treating ESRD who were not from the health system reached
14.9 billion dollars, the total cost of the ESRD reached 49.3
billion dollars in the USA. The health care system spending per
person per year an average of $75,000, ranging from $32,922
for the patient transplanted to $87,945 for those receiving he-
modialysis [1].
Diabetes is the disease that most contributes to CKD and
ESRD worldwide, accounting for 30e50% of all cases [3].
Because diabetic nephropathy is already the most common
cause of CKD, a signiﬁcant increase in the burden of this disease
can be expected. Hypertension is both a common cause, as well
as one of the main consequences of CKD. In 2000, it was esti-
mated that more than a quarter of the world's adult population
had hypertension, two thirds of them in developing countries.
It is projected that this number will increase ~60% to 1.56 billion
in 2025 [4]. Hypertension control is weak in the presence of
CKD as referred to “Kidney Early Evaluation Program”, in which
only 13.2% achieved good blood pressure control [5]. The high
risk of cardiovascular morbidity and mortality in people with
these diseases, as well as in the elderly and obese is well
established and often precedes progression to ESRD and dial-
ysis [6e9]. Historically, cardiovascular death associated with
CKD was attributed to complications of atherosclerotic disease
[10]. A substantial proportion of deaths from heart disease,
however, is not directly linked to myocardial infarction (MI),
stroke, or heart failure (HF), suggesting the presence of other
processes that contribute to cardiovascular mortality [11e13].
Recently, renal dysfunction was assessed as an independent
risk factor for sudden cardiac death (SCD), which has been
considered as a distinct end point in several cohort studies and
clinical trials.
Coronary artery disease (CAD) or congestive HF signiﬁcantly
increases the risk of SCD in the general population [14,15]. Both
the left ventricular dysfunction as the functional class (New
York Heart Association) are important risk factors for SCD and
were incorporated as clinical and diagnostics parameters that
guide the implant of automatic implantable cardioverter-
deﬁbrillator (ICD) for primary prevention of SCD [16]. Most
patients who experienced a cardiac arrest, however, does not
have a left ventricular ejection fraction (LVEF) documented
<35% before the SCD and therefore would not fulﬁll criteria for
ICD implantation [17,18].
SCD, CKD, and epidemiology
Initial studies demonstrate an increased risk of SCD in pa-
tients with kidney disease from clinical trial subgroup analyses
to assess the effectiveness of ICDs. The “Multicenter Automatic
Deﬁbrillator Implantation Trial II”, which evaluated the beneﬁt
of therapy with implantation of prophylactic ICD in patients
with prior MI and a LVEF  35% [19], investigated the risk of
SCD among patients with CKD. Among the participants sub-
mitted only to optimized drug therapy, the risk of SCD was 17%
higher for every 10 mL/min/1.73 m2 of decrease in estimated
glomerular ﬁltration rate (eGFR) [20]. Likewise, in “Comparison
of Medical Therapy, Pacing, and Deﬁbrillation in Heart Failure
Trial” [21], which demonstrated the beneﬁt of cardiac
resynchronization therapy in reducing death or hospitalization
in patients with advanced HF and cardiac electrical conduction
disease, renal dysfunctionwas associatedwith a 67% higher risk
for SCD during the 16-month follow-up period [22]. Similarstudies carried out in populations of most intermediate risk
with CAD and without HF also demonstrate an independent
association between renal dysfunction and SCD [23,24]. Despite
these ﬁndings, the presence of HF, systolic and/or CAD that
were necessary for the entry into such studies prevented an
understanding of renal dysfunction was a marker of severity of
heart disease or an independent risk factor for SCD.
Population studies have tried to understand the risk of SCD
among participants with kidney disease, minimizing the effects
of confounding prevalent CVD. Among 4,465 participants in a
community of “Cardiovascular Health Study,” without a history
of HF or MI, the incidence of SCD was 2.5 times higher with
lower levels of kidney function [22]. A more detailed analysis of
this study also usedmeasurements, creatinine and cystatin C, to
identify a predeﬁned subgroup with renal disease as a GFR
based on creatinine  60 mL/min/1.73 m2 and cystatin C  1.0
mg/L. After multivariate adjustment, the risk of SCD was twice
as high in the group with preclinical kidney disease compared
with the group who had normal renal function (eGFR based on
creatinine  60 mL/min/1.73 m2 and cystatin C < 1.0 mg/L).
These results suggest that reduction, although soft, in renal
function, increases the risk of SCD, especially in susceptible
populations such as the elderly [25].
Most cardiovascular deaths reported in the ESRD are
assigned to SCD events [26]. Some data suggest that the
arrhythmic deaths and heart attack in patients with ESRD,
combined, account for 22% of all deaths in this population [27].
Dialysis prospective cohort studies have corroborated these
ﬁndings. In “Choices for Healthy Outcomes in Caring for ESRD
trial,” 658 deaths occurred in 1,041 participants on dialysis
along 8-year follow-up. Among these 658 deaths, 146 were
because of SCD (SCD rate of 1.8% per year) [28]. In addition, a
high incidence of SCD during 5 years of longitudinal follow-up
(SCD rate of 4.9% per year) was observed in a prospective cohort
study in Chinese patients undergoing chronic peritoneal dial-
ysis [29]. Despite the slight variations in the annual rates of
SCD, about 20e25% of all causes of death were attributed to the
SCD. This relative risk is almost identical to that reported by “US
Renal Data System”, in which 25% of all causes of death among
patients on peritoneal dialysis and 27% of all causes of death
among patients on hemodialysis, in the USA, were attributed to
cardiac arrest (National Institute of Diabetes and Digestive and
Kidney Diseases, 2006).
Finally, the strong association between ESRD and SCD also
extends to the pediatric population. In a retrospective analysis
of almost 1,400 deaths among patients with ESRD and aged
0e30 years (US Renal Data System data), cardiac arrest and
arrhythmia made up most deaths related to cardiac causes,
which occurred at a rate of > 2% per year [30]. These ﬁndings
suggest that other mechanisms not related to CAD and/or HF
are responsible for triggering fatal arrhythmias in people with
ESRD.
Pathophysiology
The SCD pathophysiology is complex, and it is thought that it
requires interaction between a transient event and a pre-
existing substrate. This process induces electrical instability
and ventricular arrhythmias, followed by hemodynamic
collapse. Understanding the mechanisms that incite these
events can help clarify when the interaction between a trig-
gering event and an existing substrate proves to be harmful.
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heart, vascular calciﬁcation and ﬁbrosis, autonomic dysregu-
lation, and volume changes and electrolytes are bandied about
some of the mechanisms to explain the high predisposition to
SCD in patients with CKD. Although some of the studies that
support the proposed mechanisms have previously been con-
ducted in patients with CKD who were not on renal replace-
ment therapy, most of the data come from patients with ESRD.
Kidney disease induces cardiac remodeling including left
ventricular hypertrophy (LVH) and heart ﬁbrosis. Several clin-
ical studies, including those who recruited participants with
mild-to-moderate reduction in eGFR, showed an independent
association between CKD and LVH [31e34]. Speciﬁcally, there is
a progressive increase in the prevalence of LVH, and left ven-
tricular mass increased when the eGFR decreases. In addition,
among participants with more advanced kidney disease on
dialysis, magnetic resonance imaging (MRI) with contrast
demonstrates a diffuse pattern image with gadolinium uptake
suggestive of ﬁbrosis and nonischemic cardiomyopathy [35].
The pathogenesis of these conditions is considered multifac-
torial, and the presence of commonly associated comorbidities,
such as hypertension, diabetes mellitus, and anemia, explain
only part of the left ventricular remodeling [36e38]. The mo-
lecular basis for these changes includes activation of growth
factors, proto-oncogenes, plasma norepinephrine, cytokines,
and angiotensin II. These factors regulate intracellular pro-
cesses that accelerate cardiac hypertrophy, myocardial ﬁbrosis,
and apoptosis [39,40]. Any LVH and cardiac ﬁbrosis has been
linked to increased risk of sustained ventricular arrhythmias
and predisposition to SCD [41e45].
Kidney disease is also associated with vascular disease,
including calciﬁcation and hardening of the blood vessels
[46e49]. The decreases in eGFR and endothelial dysfunction
are inter-related processes that reduce the vascular elasticity
and subsequently increase ischemic events. Studies in humans
have shown that a deﬁcient vasodilator response that is
endothelium dependent is associated with mild renal impair-
ment [50,51]. If untreated, these conditions progress indepen-
dently and establish a cyclical relationship that results in
vascular and kidney damage. Subsequent remodeling and
sclerosis of the vessels can compromise the perfusion reserve
and increase the risk of ischemic events [52], which are com-
mon triggering factors for the onset of arrhythmias. In the
scenario of ESRD, vascular remodeling is even more pro-
nounced because the calcium phosphate deposition may
further exacerbate vascular integrity [53]. High concentrations
of phosphate and an increase in calcium phosphate product
contribute to calciﬁcation of vessels and the myocardium, as
well as for plaque instability, increasing the risk of SCD in
20e30% [54].
Structural changes can alter the electrophysiological prop-
erties of the myocardium. The myocardial ﬁbrosis disrupts the
normal architecture and results in a decrease in conduction
velocity through the diseased tissue [55]. This condition can
form heterogeneous areas of conduction and depolarization
that can sustain a re-entrant arrhythmia, such as ventricular
tachycardia [43,45,56]. These structural changes in cardiac
conduction delay ventricular activation and create late poten-
tials in the terminal portion of the QRS complex. Furthermore,
these low amplitude signals, which may be detected using a
high-resolution electrocardiogram, were identiﬁed in 25% of
patients on dialysis [57]. Several studies also evaluated QTdispersion, reﬂecting the nonhomogeneous recovery of ven-
tricular excitability, and is calculated as the difference between
the highest and lowest QT interval in a standard 12-lead elec-
trocardiogram. The QT interval dispersion is maximally
elevated in the postdialysis period [58e60] and reﬂects a
greater susceptibility to arrhythmias.
The ventricular arrhythmias and SCD in patients with ESRD
may be related to the duration of dialysis. A failure to maintain
homeostasis predisposes such patients to adverse events,
especially after a long interdialytic interval. Cardiac arrhyth-
mias and SCD are more common on Mondays and Tuesdays
after without-hemodialysis weekends and in the 12 hours after
the start of a hemodialysis session [61e64]. These ﬁndings
suggest that major changes in blood pressure, electrolyte, and
volume can induce triggers that trigger arrhythmias.
Besides dependent re-entrant arrhythmias scar forming
heterogeneous areas of electrical conduction, renal dysfunction
also increases the risk of arrhythmias, automatic or triggered by
other trigger spots [65]. These rhythms are sensitive to adren-
ergic activity. Studies in humans show that ESRD increases the
discharge rate of the sympathetic nervous system, which is
mediated by afferent signals from kidney patients [66]. This
autonomic tone increased in the setting of electrophysiological
remodeling, which explains the basis for an increased fre-
quency of premature ventricular complexes that occur in over
75% of patients with ESRD, during and after the dialysis ses-
sions [67]. Sympathetic activity in these patients probably re-
ﬂects more serious pathophysiological state because it
correlates with an increased risk of death and general cardio-
vascular events [68].
Sympathetic nervous system and renal sympathetic
denervation
Sympathetic hyperactivity is well known to increase car-
diovascular risk in CKD patients and is a hallmark of essential
hypertensive state that occurs early in the clinical course of the
disease [69e71]. In both conditions, hypertension and kidney
failure, themechanisms of hyperadrenergic state are varied and
include reﬂex and neurohumoral pathways [69,70,72]. In CKD,
the sympathetic hyperactivity seems to be expressed at the
earliest clinical stage of the disease, showing a direct relation-
ship with the severity of the condition of renal impairment
[72e75]. The increased sympathetic tone alters renal function
because of the retention volume of sodium reabsorption,
decrease in renal blood ﬂow, and activation of the
renineangiotensinealdosterone system [76]. Meta-analyses
have shown that impaired renal function is an independent
cardiovascular risk factor [77], and other studies reported that
adrenergic activation exhibits an adverse impact on cardio-
vascular morbidity and, in the case of kidney failure, also on
cardiovascular mortality [68e70,75]. Consequently, prevention
of further damage of renal function is a therapeutic target by
itself [78]. Tinucci et al evaluated basal muscle sympathetic
nerve activity (MSNA) and the sympathetic hyperactivity
mechanisms in mild chronic renal failure caused by hyperten-
sion. The baseline MSNA was signiﬁcantly higher in hyperten-
sive patients with mild renal impairment (34 bursts/min)
compared to hypertensive patients with normal renal function
(24 bursts/min, P < 0.05) and compared to normotensive pa-
tients (16 bursts/min, P < 0.05). This ﬁnding demonstrated that
the high sympathetic activity can be detected early in renal
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sympathetic denervation (RSD) in refractory patients with hy-
pertension caused a signiﬁcant reduction in blood pressure
associated with substantial and quick reduction in the indi-
vidual ﬁring properties of sympathetic vasoconstrictor ﬁbers,
using the method of MSNA, compared resistant hypertension
patients whowere not submitted for the RSD, after 3 months of
follow-up [80]. The interruption of sympathetic hyperactivity
and feedback of the renineangiotensinealdosterone system
cycle can at least partly be beneﬁcial for this population. The
RSD as well as being safe, can be considered a promising new
therapeutic strategy for patients with hypertension and CKD
[81e84], reducing the level of renin activity, aldosterone, and
angiotensin II in humans [85]. Another recent study [86], in
patients with ESRD and uncontrolled blood pressure, showed
that the RSD is feasible in these patients, and to promote a
sustained reduction in systolic blood pressure over 12 months
and signiﬁcantly decrease MSNA.
In 2012, Brandt et al showed for the ﬁrst time that beyond
the known effects on reducing blood pressure, RSD signiﬁcantly
reduced LV mass and improved diastolic function assessed by
echocardiography, which may have important implications for
prognosis in patients with resistant hypertension at high car-
diovascular risk [87]. Subsequently, Mahfoud et al [88] sub-
mitted 72 hypertensive patients refractory to cardiac MRI (55
patients underwent RSD and 17 served as controls) before and
6 months after the procedure. Clinical data and the results of
cardiac MRI were analyzed blindly. The RSD signiﬁcantly
reduced systolic and diastolic blood pressure, about 22/8
mmHg, and indexed left ventricular mass (ILVM) about 7.1%
(46.3 ± 13.6 g/m1.7 vs. 43.0 ± 12.6 g/m1.7, P < 0.001), unchanged
in the control group (41.9 ± 10.8 g/m1.7 vs. 42.0 ± 9.7 g/m1.7, P ¼
0.653). The LVEF in patients in whom this parameter was
reduced before the procedure (< 50%), it signiﬁcantly increased
after the RSD (43% vs. 50%; P < 0.001). Left ventricular
circumferential strain as a surrogate of diastolic function in the
subgroup of patients with reduced strain at baseline increased
by 21% only in the RSD group (e14.8 vs. e17.9; P ¼ 0.001) and
not in control patients (e15.5 vs. e16.4, P ¼ 0.508). In 15 of 18
(83%) nonresponders to the RSD (responsiveness to the RSD
was set to drop in systolic blood pressure10mmHg), the ILVM
was signiﬁcantly reduced from 52.1 ± 14.9 to 47.8 ± 14.4 g/m2 (P
¼ 0.001). Interestingly, the structural and functional cardiac
changes were partly independent of blood pressure, pointing to
a direct interferencemodulating the activity of the sympathetic
nervous system.
In 2014, Doltra et al [89] underwent 23 refractory hyper-
tensive patients to RSD and 5 patients served as controls,
evaluated prospectively. Cardiac MRI, 1.5 T, was performed in
all patients before and 6 months after the procedure. The
ILVM, the extracellular volume fraction of the septa, and
indexed absolute extracellular volume (a quantitative measure
of extracellular matrix) were quantiﬁed. The RSD signiﬁcantly
decreased left ventricular mass, whereas the extracellular
volume remained stable. The results suggest that the observed
decrease in left ventricular mass was not only due exclusively
to a reversal of myocyte hypertrophy but also due to a further
reduction in the collagen content, indicating myocardial
interstitial ﬁbrosis. In 2015, McLellan et al [90] underwent 14
refractory hypertensive patients to ambulatory blood pressure
monitoring (ABPM) for 24 hours, on echocardiography, cardiac
MRI, and electrophysiological study before and 6 months afterthe RSD. The electrophysiological study included duration of
measurements of the P wave, effective refractory periods, and
driving times. The electroanatomic mapping of the right
atrium was full to determine the local and regional conduction
velocity and tissue voltage. After the procedure, the mean BP
in 24-hour ABPM reduced, the global conduction velocity
signiﬁcantly increased, and the conduction time shortened.
Changes in conduction velocity showed positive correlation
changes in the mean systolic blood pressure of 24-hour ABPM.
There was also a signiﬁcant reduction in left ventricular mass
and diffuse ventricular ﬁbrosis to cardiac MRI. More recently,
D€orr et al [91] studied 100 consecutive patients with re-
fractory hypertension, and these were submitted to RSD. The
therapeutic response was deﬁned as a decrease in systolic
blood pressure of ofﬁce >10 mmHg (considered responsive
patients), 6 months after the procedure. Venous blood samples
were collected for measurement of amino-terminal propep-
tide (PINP, PIIINP) and a carboxyl terminal propeptide (PICP)
before and 6 months after the RSD. This study evaluated the
effect of renal denervation in increasing collagen absorption,
reﬂected by these speciﬁc biomarkers for resorption of cardiac
extracellular matrix and cardiovascular ﬁbrosis. A signiﬁcant
reduction in ofﬁce systolic blood pressure of 24.3 mmHg has
been documented 6 months after the RSD, as well as serum
levels of PICP, PINP, and PIIINP were signiﬁcantly lower than
baseline in patients with higher resorption of collagen,
showing differences signiﬁcant comparing responders and
nonresponders regarding the drop in blood pressure. These
results suggest a beneﬁcial effect of RSD in cardiovascular
ﬁbrosis in hypertensive heart disease and target organ injury
in high-risk patients.
For years, it is known that the control of blood pressure
reduces the rate of progression of CKD. However, only recently,
RSD emerged as a powerful tool for the control of resistant
hypertension [92,93]. This procedure has also proved effective
in controlling resistant hypertension even in patients with CKD.
In 2 studies with a short follow-up period, the RSD was asso-
ciated with increased eGFR [81,94,95] and the reduction of
albuminuria [81,94,96].
Aim and conclusion
In patients with ESRD, probably there will be no recovery of
renal function, as a recent study including patients with eGFR
< 45 mL/min/1.73 m2, did not improve this parameter 12
months after the procedure [82]. Recently, Kiuchi et al [97]
reported for the ﬁrst time the reduction in left ventricular
mass and diameter, the improvement on systolic function, and
correlation between the increase in eGFR and the reduction in
LVM 6 months after RSD in CKD patients with resistant hy-
pertension. This review aims to show that these results suggest
that the renal artery ablation in this kind of patients seems to
be effective in reducing lesions of target organs such as the
heart and kidneys. However, many of the factors discussed
previously that lead to SCD in patients with CKD in end-stage
appear to be modiﬁable by the RSD according to the afore-
mentioned studies, which would make use of this new tool to
modify such factors risk, until now not modiﬁable.
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